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Abstract
Background: Neuropsychiatric symptoms are highly prevalent in nursing home patients with dementia. Despite
modest effectiveness and considerable side effects, psychotropic drugs are frequently prescribed for these
neuropsychiatric symptoms. This raises questions whether psychotropic drugs are appropriately prescribed. The aim
of the PROPER (PRescription Optimization of Psychotropic drugs in Elderly nuRsing home patients with dementia) II
study is to investigate the efficacy of an intervention for improving the appropriateness of psychotropic drug
prescription in nursing home patients with dementia.
Methods/design: The PROPER II study is a multi-center cluster randomized controlled, pragmatic trial using parallel
groups. It has a duration of eighteen months and four six-monthly assessments. Six nursing homes will participate in the
intervention and six will continue care as usual. The nursing homes will be located throughout the Netherlands, each
participating with two dementia special care units with an average of fifteen patients per unit, resulting in 360 patients.
The intervention consists of a structured and repeated multidisciplinary medication review supported by education
and continuous evaluation. It is conducted by pharmacists, physicians, and nurses and consists of three components:
1) preparation and education, 2) conduct, and 3) evaluation/guidance. The primary outcome is the proportion of
patients with appropriate psychotropic drug use. Secondary outcomes are the overall frequency of psychotropic drug
use, neuropsychiatric symptoms, quality of life, activities of daily living, psychotropic drug side effects and adverse events
(including cognition, comorbidity, and mortality). Besides, a process analysis on the intervention will be carried out.
Discussion: This study is expected to improve the appropriateness of psychotropic drug prescription for
neuropsychiatric symptoms in nursing home patients with dementia by introducing a structured and repeated
multidisciplinary medication review supported by education and continuous evaluation.
Trial registration: Netherlands Trial Registry (NTR): NTR3569.
Keywords: Dementia, Psychotropic drugs, Nursing homes, Medication safety, Clinical trial
Background
Neuropsychiatric symptoms (NPS) are highly prevalent
in and burdensome for nursing home patients with
dementia. Studies show prevalence rates of clinically
relevant NPS of over 70% [1,2], and a cumulative two-year
prevalence of even 97% [3]. NPS comprise a wide range
of heterogeneous symptoms including delusions, halluci-
nations, agitation/aggression, depression, apathy, euphoria,
anxiety, disinhibition, irritability, and aberrant motor
behavior, which are frequently treated with psychotropic
drugs. It is known that the efficacy of psychotropic drugs
is limited and that their use is associated with consider-
able side effects such as extrapyramidal symptoms, som-
nolence, and increased risk for stroke, pneumonia, and
mortality [4-7].
Nevertheless, the prevalence of psychotropic drug use
(PDU) among nursing home patients with dementia is
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high with rates ranging from 48 to 66% [8-10]. More-
over, there is a risk for long-term use of psychotropic
drugs whereas prescription for only a short period of time
is recommended [4,11]. For instance, 74% of the nursing
home patients with dementia use antipsychotics, anxio-
lytics, hypnotics, or sedatives for 83% of the duration of
their stay [12], and 31% continue the use of antipsychotics,
antidepressants, anxiolytics, hypnotics, anticonvulsants, or
anti-dementia drugs throughout a 2-year period [9]. The
contradiction of widely prescribed psychotropic drugs
despite side effects and limited evidence for (long-term)
effectiveness, suggests that psychotropic drugs may be
prescribed inappropriately.
Systematic reviews on the effect of education, the in-
volvement of pharmacists, and/or a multidisciplinary team
show that these interventions may improve drug prescrip-
tion in the elderly [13] or in nursing homes specifically
[14,15]. For instance, improvements of about 30% in the
prescription of drugs in nursing home residents [16,17],
and discontinuation or dose reduction of antipsychotics
in 61% of patients with dementia [18] have been found.
Since the above-mentioned systematic reviews also in-
clude high quality studies not showing an effect, the au-
thors suggest to focus in future studies on for example
combining methods, multidisciplinary cooperation and
direct communication between pharmacist, physician,
and nurse, ways to improve the intervention, continuous
education, and explicit procedures and routines for medi-
cation review. This encouraged us to develop an inter-
vention integrating these elements into a new method of
medication review. This medication review will be con-
ducted face-to-face by a multidisciplinary team including
not only the physician and pharmacist but also a member
of nursing staff. Further, it will be supported by edu-
cation on practical, organizational, and medical aspects,
continuous evaluation, and will be repeated every six
months. It is expected that the education and continuous
evaluation offered to all participants gives each of them
additional knowledge and structure for proper medi-
cation review with a specific emphasis on psychotropic
drugs. Furthermore, the participation of nurses, through
their daily observations representing the patient, and the
face-to-face setting is expected to improve the quality of
the review.
The PROPER II study (PRescription Optimization of
Psychotropic drugs in Elderly nuRsing home patients
with dementia) aims to study the effect of a structured
and repeated multidisciplinary medication review sup-
ported by education and continuous evaluation on the
appropriateness of PDU for treatment of NPS in nursing
home patients with dementia. Secondary objectives are
to investigate NPS, quality of life, activities of daily liv-
ing, side effects and adverse events (including cognition,
hospitalizations, and mortality).
Methods/design
Design and eligibility
The study is a multi-center, cluster randomized controlled,
pragmatic trial using parallel groups, with a duration of
eighteen months, and four six-monthly assessments. Six
nursing homes will participate in the intervention and six
will continue care as usual. Randomization will be con-
ducted on the level of nursing homes to prevent contam-
ination bias within the nursing home. The nursing homes
will be located throughout the Netherlands, and each will
participate with two dementia special care units (DSCUs).
In the Netherlands, dementia patients usually reside on
DSCUs, and medical care including prescription of psy-
chotropic drugs is provided by an elderly care physician
employed by the nursing home [19]. In an investiga-
tion preceding the PROPER II study, the observational
PROPER I study, the same twelve nursing homes will
participate. Nursing homes will be selected based upon
their responses on a questionnaire regarding the pro-
portion of patients using psychotropic drugs per indi-
vidual DSCU. In order to maximize variation in the use
of psychotropic drugs in the PROPER II study, those
nursing homes, more specifically, those DSCUs with
either high or low rates, will be approached for partici-
pation. Ideally, six nursing homes with high PDU, and
six with low PDU will be included. Since the sample
size needed for PROPER II (see below) is lower than for
the PROPER I study [20], two DSCUs from each par-
ticipating nursing home will be randomly included in
the current study.
In total, 360 patients with a chart diagnosis of dementia
will be included, i.e. on average fifteen patients of each of
two DSCUs of twelve nursing homes. From DSCUs with
more than fifteen patients, a random selection of fifteen
patients will be included, regardless of their PDU. For
DSCUs with less than fifteen patients, additional DSCUs
will participate to retrieve the warranted number of pa-
tients per nursing home. Patients who die or are dis-
charged from the DSCU, will be replaced during the
study period. Physicians and nurses who are directly in-
volved in the medical treatment and care for the patients
will collect the patient data.
This study is a collaboration between the sections for
elderly care medicine of three Dutch university Medical
Centers and the Dutch Institute for Rational Use of
Medicine [21], and is supported by the Dutch association
for residential and home care organizations (ActiZ), and
the Dutch Health Care Inspectorate.
Intervention
The intervention consists of a structured and repeated
multidisciplinary medication review supported by edu-
cation and continuous evaluation. It consists of three
components: 1) preparation and education, followed by a
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cycle of 2) conduct and 3) evaluation/guidance (Figure 1).
A local project coordinator will be assigned to ensure
appropriate planning and organization of these compo-
nents. The first component takes place within one month
after the baseline assessment of the trial; the second occurs
within one month after the first component, or within one
month after the evaluation/guidance meeting of the third
component; the third component takes place within one
month after the six- and twelve-month trial-assessments.
Component 1: preparation and education
The first component includes all preparations prior to
the actual conduct of the medication review. The major
part consists of an educational session. The education
includes both the practical and organizational aspects of
the medication review, as well as training about the effi-
cacy and side effects of psychotropic drugs. It will be
provided locally at each intervention nursing home and
is to be attended by physicians, pharmacists, and nurses.
The content is based upon the Guideline for problem
behavior of the Dutch Association of Elderly Care Physi-
cians and Social Geriatricians (Verenso) [22], and the
Multidisciplinary guideline Polypharmacy in the elderly
[23] including the STRIP method and Dutch versions of
the START and STOPP tools [24]. The STRIP is the Sys-
tematic Tool to Reduce Inappropriate Prescribing and
is a guidance for conducting structured medication re-
views, the START is the Screening Tool to Alert doctors
to Right Treatment, and the STOPP is the Screening
Tool of Older Person’s potentially inappropriate Pre-
scriptions. This education will be provided by the Dutch
Institute for Rational Use of Medicine (IVM), which is
specialized in the distribution of information and solu-
tions for the proper, safe, affordable and effective use of
medicine. The education is developed by the IVM in co-
operation with the authors. Next to the education, this
Component 1: Preparation and education
• Education on practical and organizational aspects of medication review, as well 
as on efficacy and side effects of psychotropic drugs
• Planning of responsibilities and timelines
• Definition of sources of information to be used during medication reviews 
Component 2: 
Conduct
• Individual preparation 
of the medication 
review
• Discussion during 
medication review 
meetings
• Handling of proposed 
changes and actions
• Follow-up of changes
Component 3: 
Evaluation/guidance
• Evaluation meeting
• Availability of helpdesk
Figure 1 Intervention of the structured and repeated multidisciplinary medication review supported by education and continuous
evaluation, consisting of three components.
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component comprises assigning responsibilities of the
physicians, pharmacists, and nurses involved, timelines
to be followed, and defining those sources of information
that each of the participants will use for the medica-
tion review.
Component 2: conduct
The second component includes the actual conduct of
the medication review and follow-up per individual pa-
tient. The structure is largely based on the STRIP [23].
The conduct of medication reviews per individual patient
is a process of preparation, discussion on medication dur-
ing the medication reviews, execution of the actions pro-
posed, and evaluation of changes. The medication review
will be conducted by a team consisting of an (elderly
care) physician, pharmacist, and a nurse (assistant). Each
of the participants will prepare the medication review.
The physician is responsible for collecting medical data
of the patient relevant for the discussion, such as type
of dementia, comorbidity, and contraindications. The
pharmacist is accountable for the actual medication
list, knowledge on drug-drug interactions, and dosages.
Whereas the STRIP involves the patient in the prepar-
ation of the medication review, the patient is in this
study represented by the nurse. The nurse is therefore
responsible for collecting information about the pa-
tient’s current behavior and potential PDU-related side
effects and adverse events by means of completing a
checklist per patient prior to the medication review.
The medication review focuses on the appropriate pre-
scription of psychotropic drugs for NPS, but also includes
review of other drugs. During the discussion, the team de-
termines whether (psychotropic) drugs must be addition-
ally prescribed, tapered, discontinued, dose-adjusted, or
replaced, and whether other actions are needed. These en-
compass additional diagnostics such as blood checks or
electrocardiography, further observations of side effects
and adverse events or NPS, referral to a psychologist or to
a medical specialist, and use of psychosocial interventions
by nursing staff in behavioral management. Proposed
changes and actions will be registered and implemented
after obtaining consent from the patient’s representative.
(Non)compliance to the proposed actions is also registered.
Further, changes in medication will be followed-up con-
tinuously by the physician and nurse.
Component 3: evaluation/guidance
Evaluation meetings regarding the conduct of the medi-
cation reviews will be organized to provide continous
evaluation by guiding and counseling in the process of
medication review. These meetings will be provided by
the IVM and are to be attended by physician, pharmacist
and nurse. Moreover, a help desk provided by the IVM
is available for questions.
Outcomes
Primary outcome
The primary outcome is the appropriateness of PDU de-
fined as the proportion of patients with appropriate PDU.
Assessment of appropriateness in this study is limited to
antiepileptics, antipsychotics, anxiolytics, hypnotics/seda-
tives, antidepressants, and anti-dementia drugs prescribed
for treatment of NPS in dementia, for sleep disturbances,
and for delirium. Based on the Medication Appropriate-
ness Index [25], a scale will be developed specifically for
those psychotropic drugs used for treatment of NPS in
nursing homes. Information will be included from the
Guideline for problem behavior of the Dutch Associ-
ation of Elderly Care Physicians and Social Geriatricians
(Verenso) [22], the Guideline for diagnostics and medical
treatment of dementia of the Dutch Geriatrics Society [26],
the drug database of the Royal Dutch Pharmacists Associ-
ation [27], and the ‘Farmacotherapeutisch Kompas’ [28], a
reference of drugs available in the Netherlands published
by the Dutch Health Care Insurance Board (CVZ).
Secondary outcomes
Secondary outcomes are the overall frequency of PDU,
NPS, quality of life, activities of daily living, psychotropic
drug side effects and adverse events (including cogni-
tion, hospitalizations, and mortality).
The overall frequency of PDU will be collected from
the patients’ medical files or from (prints of) the electronic
pharmacist information system and categorized using
the Anatomical Therapeutic Chemical (ATC) classification
[29] into the following therapeutic subgroups: antiepilep-
tics (N03A), antipsychotics (N05A), anxiolytics (N05B),
hypnotics and sedatives (N05C), antidepressants (N06A),
and anti-dementia drugs (N06D).
NPS will be assessed using the Neuropsychiatric
Inventory – Questionnaire (NPI-Q), the Cohen-Mansfield
Agitation Inventory (CMAI), the Nijmegen Observer-
Rated Depression scale (NORD), and the Minimum Data
Set Depression Rating Scale (MDS-DRS). The NPI-Q [30]
is a brief version of the Neuropsychiatric Inventory, which
was developed for measuring NPS in dementia [31]. The
NPI-Q consists of twelve items on NPS, each scored for
occurrence (yes/no format), severity (three-point Likert
scale), and associated caregiver distress of NPS (six-point
Likert scale). A validated Dutch version will be used [32].
The CMAI is a questionnaire on 29 agitated behaviors
reflecting physical aggression, physically nonaggressive be-
havior, and verbally agitated behavior. All items regard fre-
quency of behavior using a seven-point Likert scale [33].
The (construct) validity of the Dutch version [34,35] and
reliability [36] have been extensively studied. The NORD is
a recently developed and promising Dutch questionnaire
on occurrence (yes/no format) of five observable depressive
symptoms, for screening of depression in nursing home
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residents with or without dementia [37]. The MDS-DRS is
a seven-item observational instrument consisting of seven
items on depression derived from the Minimum Data
Set of the Resident Assessment Instrument (MDS-RAI)
[38,39]. Each item is scored for frequency on a three-point
scale. The Dutch version of this instrument was studied
for validity and reliability and considered suitable for re-
search in nursing homes [40].
Quality of life will be assessed using the Qualidem, a
37-item observational instrument consisting of nine sub-
scales for measuring quality of life, each item is scored for
frequency on a four-point scale. It was developed for Dutch
nursing home patients with dementia and proven reliable
and valid [41,42]. In order to allow proper interpretation of
the Qualidem scores, the severity of dementia will be
assessed using the Global Deterioration Scale, a staging in-
strument indicating cognitive deterioration in dementia
[43]. Additionally, the Revised Index of Social Engagement
(RISE) [44] will be assessed. This is an observational instru-
ment with six dichotomous items on social behavior, which
is considered to contribute to quality of life. The RISE is a
revised version of the Index of Social Engagement [45],
and is derived from the MDS-RAI [38,46].
Activities of daily living will be assessed using a ques-
tionnaire also derived from the MDS-RAI [47], of which
validity and reliability of the Dutch version were estab-
lished [40]. This scale has been adapted for the Dutch
nursing home situation and scoring was simplified, result-
ing in a scale of twelve items to be scored on a four-point
scale for level of independence, and a thirteenth item re-
garding change compared with the previous month (Joke
Smallenburg, personal communication 2011).
Psychotropic drug side effects and adverse events will
be assessed by symptoms and disorders related to PDU,
cognition, hospitalizations, and mortality. A scale repre-
senting common symptoms and disorders related to PDU
will be developed for this study, based upon the Udvalg for
kliniske undersogelser side effect rating scale (UKU) [48].
Cognition will be assessed using the Severe Impairment
Battery-8 [49], a brief version of the Severe Impairment
Battery [50]. It was developed as a brief instrument for pa-
tients with severe Alzheimer’s disease and is sensitive to
change over time. The SIB-8 was translated into Dutch for
this study. Hospitalizations will be assessed by the number,
indication, and duration as reported by the physicians, and
mortality will be derived from the patients’ medical files.
All assessments will take place at baseline, six months,
twelve months and eighteen months. An overview of the
outcomes is shown in Table 1.
Baseline characteristics
Other characteristics collected at baseline will be: age,
sex, duration of nursing home admission, type of demen-
tia as documented in the patients’ files, and comorbidity.
Comorbidity will be assessed using a checklist on 25
chronic diseases considered most prevalent in a nursing
home population. This checklist is a selection of those
International Classification of Primary Care (ICPC) chronic
diseases and comorbidities that are most prevalent in gen-
eral practice [51], and adapted for the PROPER II study.
Process analysis
Also, a process analysis will be carried out on the actual
use of the intervention and the factors determining its im-
plementation, especially regarding facilitators and barriers.
In addition, reasons for non-compliance with the interven-
tion and time spent on medication review will be assessed,
and the meetings guided by the IVM will be evaluated.
Separate checklists for nurses, physicians, pharmacists, as
well as for the nursing home’s local project coordinator will
be used.
Sample size
Assuming an increase in the proportion of patients with
appropriate PDU from 60% to 80% in the intervention
group and equal randomization to the intervention or con-
trol group, a significance level (alpha) of 0.05, a power of
80%, an average cluster size of fifteen patients per DSCU,
and an ICC of 0.05 [52], a sample size of 21 clusters is suf-
ficient to detect a statistically significant difference applying
Russ Lenth software [53] and calculation methods accord-
ing to Twisk [54]. Allowing for a DSCU drop-out of ten
percent, in total 23 clusters are needed, resulting in the in-
clusion of two DSCUs in each of twelve nursing homes.
Statistical analysis
Multilevel analysis will be applied to study the change in
the proportion of patients with appropriate PDU between
baseline and the average at six, twelve, and eighteen months
on intervention DSCUs and control DSCUs, after correc-
tion of relevant covariates, such as baseline PDU and NPS.
The use of a multilevel model will be applied for a number
of reasons: patient PDU is hypothesized to be dependent
on the prescription policy of the physician and thus to be
nested within DSCUs, the longitudinal design and cluster
randomization, and the replacement of drop-outs.
Ethics approval
The local Medical Ethics Review Committee ‘CMO Regio
Arnhem-Nijmegen’ rated the study (number 2012/226)
and pronounced that the study is in accordance with the
applicable rules in the Netherlands concerning the review
of research ethics committees and informed consent. Rep-
resentatives of all selected patients will be approached in
writing to inform them about the study and to give them
the explicit opportunity to refrain from participation of the
patient in the study. The study will be conducted in ac-
cordance with the Declaration of Helsinki [55].
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Discussion
This protocol presents the design of a cluster randomized
controlled trial evaluating the effectiveness of a struc-
tured and repeated multidisciplinary medication review
supported by education and continuous evaluation to im-
prove appropriate prescription of psychotropic drugs for
NPS in nursing home patients with dementia.
The strength of this study’s intervention is the multi-
disciplinary three-component approach of involving pro-
fessionals who are educated to carry out a structured
and repeated medication review. By including not only
the pharmacist and physician but also the nurse, the multi-
disciplinary team is expected to bring optimal knowledge
from different perspectives. In this setting, not only med-
ical and pharmaceutical expertise is taken into account,
but also insight into the patients’ NPS, for which the psy-
chotropic drugs are prescribed. Besides, the nurse has close
contact with the representative of the patient, which fur-
ther allows input on wishes regarding treatment or accep-
tation of NPS for the individual patient to be included in
the medication review. Moreover, this study is a broad col-
laboration between several Dutch parties. Aside from the
sections for elderly care medicine of three Dutch university
Medical Centers, which have close connections with nu-
merous nursing homes, the Dutch Institute for Rational
Use of Medicine, the Dutch association for residential and
home care organizations (ActiZ), and the Dutch Health
Care Inspectorate are actively involved in this project. This
has not only contributed to the design of the study and
structure of the intervention, but will also facilitate the
knowledge transfer of the results to daily practice after
completion of the study. In case effectiveness of this three-
component intervention is shown, this medication review
method will be used on a broader scale to increase aware-
ness of physicians, pharmacists and nurses of proper psy-
chotropic drug use.
The study may have some limitations. Firstly, the involve-
ment of a pharmacist for medication review is currently
starting to become part of usual care, also in the control
nursing homes. However, these medication reviews are
most likely not introduced in a similar education-based,
structured, and multidisciplinary fashion. Secondly, the
turn-over of pharmacists, physicians, and/or nurses will
affect the knowledge regarding the proposed conduct of the
medication reviews, in case new staff did not attend the
education sessions. However, due to the pragmatic design,
the study will have a large external validity and it is ex-
pected that a potential effect is at least not overestimated.
Concluding, in the PROPER II study we target to im-
prove the quality of pharmacological treatment of NPS
of nursing home patients with dementia, by implement-
ing a sound intervention of a structured and repeated
multidisciplinary medication review supported by educa-
tion and continuous evaluation.
Table 1 Overview of outcomes, instruments, and assessor at baseline, six, twelve, and eighteen months
Outcome Instrument Assessor
Appropriateness of PDU To be developed Researcher
Frequency of PDU Generic name and ATC code Researcher
NPS
NPS NPI-Q Nurse
Agitation/aggression CMAI Nurse
Depression NORD Nurse
Depression MDS-DRS Nurse
Quality of life
Quality of life Qualidem Nurse
(For interpretation of Qualidem) GDS Physician
Social engagement RISE Nurse
Activities of daily living Instrument derived from MDS-RAI Nurse
Psychotropic drug side effects and adverse events
Symptoms and disorders related to PDU Instrument derived from UKU Physician
Cognition SIB-8 Physician/representative
Hospitalizations Number, indication, and duration Physician
Mortality Occurrence Researcher
Abbreviations: PDU psychotropic drug use, ATC Anatomical Therapeutic Chemical, NPS neuropsychiatric symptoms, NPI-Q Neuropsychiatric Inventory – Questionnaire,
CMAI Cohen-Mansfield Agitation Inventory, NORD Nijmegen Observer-Rated Depression scale, MDS-DRS Minimum Data Set Depression Rating Scale, GDS Global
Deterioration Scale, RISE Revised Index of Social Engagement, MDS-RAI: Minimum Data Set Resident Assessment Instrument, UKU Udvalg for kliniske undersogelser
side effect rating scale, SIB-8 Severe Impairment Battery-8.
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